DTRMWXHS 12
Alternative Names: DTRM-12; DTRMWXHS12Latest Information Update: 28 Mar 2022
At a glance
- Originator Zhejiang DTRM Biopharma
- Class Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- No development reported B-cell lymphoma; Mantle-cell lymphoma
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Mantle-cell-lymphoma(Second-line therapy or greater) in China (PO, Capsule)
- 17 Nov 2021 Zhejiang DTRM Biopharma completes a phase I/II trial in Mantle-cell lymphoma (In adults, Refractory metastatic disease, Recurrent) in China (PO) (NCT03836768)
- 05 Dec 2020 Additional safety and efficacy data from a phase I trial in Diffuse large B-cell lymphoma presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology